Overview

Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purposes of this Phase 1/2 study are to examine the safety, tolerability, and antiviral activity of ISIS 14803, when given in combination with peginterferon alfa and ribavirin, to patients who either failed to have at least a 100-fold HCV reduction at Week 12 of standard therapy or still have detectable HCV at Week 24.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Treatments:

Ribavirin